Eli Lilly and Company (NYSE:LLY) Shares Purchased by State of Alaska Department of Revenue

State of Alaska Department of Revenue raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 96,339 shares of the company's stock after purchasing an additional 2,390 shares during the quarter. Eli Lilly and Company accounts for approximately 0.9% of State of Alaska Department of Revenue's investment portfolio, making the stock its 13th biggest holding. State of Alaska Department of Revenue's holdings in Eli Lilly and Company were worth $79,566,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Capital & Planning LLC grew its position in Eli Lilly and Company by 15.6% during the fourth quarter. Capital & Planning LLC now owns 481 shares of the company's stock valued at $371,000 after buying an additional 65 shares during the period. Garner Asset Management Corp raised its position in shares of Eli Lilly and Company by 2.3% in the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after acquiring an additional 12 shares during the period. Brighton Jones LLC boosted its stake in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $49,534,000. Finally, Revolve Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after acquiring an additional 40 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $6.96 during midday trading on Thursday, hitting $784.28. The company's stock had a trading volume of 2,441,727 shares, compared to its average volume of 3,656,357. The company has a market cap of $743.29 billion, a P/E ratio of 63.81, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The business's 50 day simple moving average is $778.55 and its 200 day simple moving average is $801.58. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period last year, the business earned $2.58 earnings per share. On average, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company's payout ratio is 48.82%.

Analyst Ratings Changes

A number of research firms recently weighed in on LLY. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, June 7th. UBS Group reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their target price for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Finally, Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.